Soleno Therapeutics, Inc. (SLNO)
Largest Insider Buys in Sector
SLNO Stock Price History Chart
SLNO Stock Performance
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and …
Insider Activity of Soleno Therapeutics, Inc.
Over the last 12 months, insiders at Soleno Therapeutics, Inc. have bought $0 and sold $119.93M worth of Soleno Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Soleno Therapeutics, Inc. have bought $13.51M and sold $27.01M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 250,000 shares for transaction amount of $5M was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2023‑09‑28.
List of Insider Buy and Sell Transactions, Soleno Therapeutics, Inc.
| 2024-10-01 | Sale | CHIEF EXECUTIVE OFFICER | 21,633 0.0564% | $49.43 | $1.07M | +8.05% | ||
| 2024-10-01 | Sale | CHIEF FINANCIAL OFFICER | 8,077 0.0211% | $49.43 | $399,241 | +8.05% | ||
| 2024-10-01 | Sale | SEE REMARKS | 3,108 0.0081% | $49.43 | $153,627 | +8.05% | ||
| 2024-10-01 | Sale | SEE REMARKS | 3,108 0.0081% | $49.43 | $153,627 | +8.05% | ||
| 2024-08-29 | Sale | 10 percent owner | 100,000 0.2609% | $47.22 | $4.72M | +11.03% | ||
| 2024-08-29 | Sale | CHIEF EXECUTIVE OFFICER | 58,391 0.1525% | $47.28 | $2.76M | +11.03% | ||
| 2024-08-29 | Sale | CHIEF FINANCIAL OFFICER | 6,870 0.0179% | $47.28 | $324,845 | +11.03% | ||
| 2024-08-29 | Sale | SEE REMARKS | 5,435 0.0142% | $47.28 | $256,992 | +11.03% | ||
| 2024-08-29 | Sale | SEE REMARKS | 5,435 0.0142% | $47.28 | $256,992 | +11.03% | ||
| 2024-08-28 | Sale | 10 percent owner | 425,000 1.101% | $47.35 | $20.12M | +9.76% | ||
| 2024-08-28 | Sale | CHIEF EXECUTIVE OFFICER | 56,613 0.1474% | $47.58 | $2.69M | +9.76% | ||
| 2024-08-28 | Sale | CHIEF FINANCIAL OFFICER | 6,661 0.0173% | $47.58 | $316,938 | +9.76% | ||
| 2024-08-28 | Sale | SEE REMARKS | 5,270 0.0137% | $47.58 | $250,753 | +9.76% | ||
| 2024-08-28 | Sale | SEE REMARKS | 5,270 0.0137% | $47.58 | $250,753 | +9.76% | ||
| 2024-08-27 | Sale | 10 percent owner | 500,000 1.2782% | $48.73 | $24.36M | +4.78% | ||
| 2024-08-06 | Sale | CHIEF EXECUTIVE OFFICER | 69,131 0.1847% | $45.46 | $3.14M | +8.71% | ||
| 2024-08-06 | Sale | CHIEF FINANCIAL OFFICER | 8,134 0.0217% | $45.46 | $369,736 | +8.71% | ||
| 2024-08-06 | Sale | SEE REMARKS | 5,977 0.016% | $45.46 | $271,689 | +8.71% | ||
| 2024-08-06 | Sale | SEE REMARKS | 5,957 0.0159% | $45.46 | $270,780 | +8.71% | ||
| 2024-08-05 | Sale | CHIEF EXECUTIVE OFFICER | 58,213 0.1616% | $45.77 | $2.66M | +12.02% |
Insider Historical Profitability
| Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | 719553 1.6688% | $45.18 | 4 | 13 | <0.0001% |
| Mackaness James H | CHIEF FINANCIAL OFFICER | 119172 0.2764% | $45.18 | 3 | 11 | <0.0001% |
| Abingworth LLP | 10 percent owner | 18022602 41.7989% | $45.18 | 3 | 0 | +8.21% |
| Sinclair Andrew | 18022602 41.7989% | $45.18 | 4 | 0 | +23.93% | |
| ENGLEMAN EDGAR | 4033540 9.3548% | $45.18 | 2 | 0 | +22.67% |
Institutional Investor Ownership
| Vivo Capital | $360.29M | 24.28 | 8.42M | 0% | +$0 | 31.38 | |
| The Carlyle Group | $173.12M | 11.74 | 4.07M | +42.47% | +$51.61M | 7.43 | |
| Perceptive Advisors | $131.59M | 8.87 | 3.07M | 0% | +$0 | 0.09 | |
| Janus Henderson | $122.7M | 8.28 | 2.87M | +13.74% | +$14.83M | 0.06 | |
| Nantahala Capital Management Llc | $103.16M | 6.95 | 2.41M | -15.61% | -$19.09M | 4.8 |